Plasma NGAL level
PreclinicalBiologic
Plasma NGAL level is one of 40 biologic programs targeting Headache. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Cataflam
NovartisPreclinical
Rituxan
PfizerPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rheumatoid Arthritis1 trial
Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis
Completed·—··NCT01961310·55 enrolled
Headache1 trial
S100B in the Care of Non-traumatic Headaches in the Emergency Department
Completed·—·N/A·NCT02683304·81 enrolled
Rhabdomyolysis1 trial
Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
Completed·—··NCT01544231·197 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Plasma NGAL level. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details